newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - DENALI THERAPEUTICS INC

  • Financial Performance:

    • U.S. Hunter Syndrome (MPS II) launch is described as "very successful" with strong community uptake.
    • Annual pricing in the U.S. for a 30kg patient is approximately $800,000, representing a ~60% premium over the incumbent Elaprase ($500,000).
    • Q4 2025 revenue guidance is provided for the first time, set at $30–32 million.
    • Management confirmed quarterly revenue guidance will be provided for 2026 to clarify launch trajectory; 2027 guidance is not yet disclosed.
    • Revenue generation from Avlea extends the company's cash runway.
    • No specific figures on total cash, debt, or margins were disclosed in this transcript.
  • Guidance and Future Outlook:

    • BLA filing for Sanfilippo Syndrome (MPS III) expected in 2026.
    • Key data readouts scheduled for:
      • COMPAS study (Head-to-head vs. Elaprase in Hunter Syndrome): End of 2026 for two-year endpoints, with potential market access in 2028.
      • Sanfilippo Phase 2 full dataset (20 patients): World Molecular Medicine meeting in February 2027.
      • Progranulin (FTD) dataset: First half of 2027.
      • Alzheimer's Tau and Beta-amyloid (DNL921) early biomarker data: 2027.
    • Long-term goal is to expand Avlea label to include adults (currently 25% of the population, >30% of value) and secure international approvals.
    • Management aims to become the market leader in Hunter Syndrome, treating all new patients and capturing significant share from existing ERT users.
  • Business Segments and Product Lines:

    • Avlea (Hunter Syndrome): The first commercial product; utilizes the transport vehicle platform to cross the blood-brain barrier (BBB). Currently approved for pediatric patients; seeking adult expansion.
    • Sanfilippo (MPS III): Enzyme transport vehicle candidate; early data shows 80% reduction in CSF heparan sulfate and normalization in a subset of patients. Confirmatory Phase 3 study design is being finalized, potentially leveraging historical controls following recent gene therapy approvals.
    • Progranulin (FTD): Protein replacement therapy for Granulin mutation FTD; treatment duration extended from 6 to 12 months to capture neurofilament light chain (NFL) biomarker changes.
    • Alzheimer's Portfolio:
      • Tau (DNL921): IV delivery using transport vehicle for even brain distribution; targeting >20-50% CSF tau reduction.
      • Beta-amyloid: Uniquely engineered antibody with "on-off switch" mechanism to minimize immunogenicity and hematological side effects (reticulocytes); aiming for sub-Q dosing.
    • Pompe Disease: Mentioned as an important readout in the pipeline.
  • Market and Competitive Landscape:

    • Hunter Syndrome: Addressable U.S. population is ~375 patients (75% of total ~500) under current label; global population estimated at ~2,000. Incumbent Elaprase generates ~$700M globally; Denali expects to exceed this total.
    • Competitive Advantage: Avlea's BBB penetration and superior biomarker reduction (heparan sulfate) vs. Elaprase's lack of CNS efficacy.
    • Alzheimer's: Differentiation lies in the transport vehicle technology enabling even brain distribution and sub-Q dosing, contrasting with intrathecal delivery (Biogen) and traditional antibody approaches with hematological risks.
    • Regulatory Environment: Shifting landscape with Ultragenyx's gene therapy approval using natural history comparators; Denali actively engaging FDA to align Phase 3 designs for Sanfilippo.
  • Risks and Challenges:

    • Regulatory Hurdles: Need for label expansion into adults and international markets (COMPAS study required for many ex-U.S. regions).
    • Clinical Trial Design: Sanfilippo study design must adapt to the new regulatory bar set by recent gene therapy approvals and potential use of historical controls.
    • Biomarker Thresholds: Uncertainty regarding the specific magnitude of NFL or tau reduction required for accelerated approval.
    • Patient Selection: Critical need to capture Sanfilippo patients early in the disease course before severe progression; heterogeneity in patient mutations and disease progression.
    • Competition: Emerging gene therapies and amyloid/tau inhibitors in Alzheimer's.
  • Management Commentary and Tone:

    • Tone is highly confident and enthusiastic, emphasizing the validation of the "transport vehicle" platform.
    • Management highlights "overwhelming" positive feedback from patient families and physicians regarding Avlea.
    • CEO Ryan Watts and CCO Katie Payne express strong belief that Avlea will become the standard of care and exceed Elaprase revenues.
    • CFO Alex Shuth provided precise revenue guidance, signaling a transition to a commercial-stage company.
    • Emphasis on the strategic value of the platform's ability to treat both pediatric and adult indications and to reach the brain safely.
  • Analyst Questions and Answers:

    • Pricing vs. Competitor: Confirmed $800k vs. $500k annual cost in U.S.
    • Growth Trajectory: Management committed to quarterly guidance for 2026; 2027 guidance pending.
    • COMPAS Study Details: 65 patients, two cohorts (neurologic and somatic/adults); head-to-head with Elaprase using Vineland (behavior) and HS biomarker co-primary endpoints.
    • Sanfilippo Dosing: Learning that more frequent dosing improves tolerability; 80% biomarker reduction achieved in early cohort.
    • Alzheimer's Differentiation: Clarified that IV transport vehicle offers even distribution unlike intrathecal methods, expecting better clinical correlation with CSF biomarkers.
    • Sub-Q Dosing: A major strategic goal for Alzheimer's and potentially other programs, though timing specifics were deferred ("stay tuned").
  • Other Key Points:

    • The "transport vehicle" platform is the core value proposition, validated by Avlea and applicable across the entire pipeline (Hunter, Sanfilippo, FTD, Alzheimer's, Pompe).
    • The Sanfilippo Phase 2 data presentation will include 20 patients (8 initial + 12 additional), with 12 pre-specified as the to-be-marketed dose cohort.
    • Management noted that in FTD, NFL reduction is a strong predictor of clinical benefit, citing Tofersen's ALS approval as precedent.
    • The DNL921 Alzheimer's antibody uses an integrated TFR binding mechanism rather than linkers, theoretically improving stability and brain uptake compared to conventional formats.
Company
DENALI THERAPEUTICS INC
Keywords
DENALI THERAPEUTICS INC